Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the
DELIVER
trial
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-06-04
DOI
10.1002/ejhf.2249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial
- (2021) Michael E. Nassif et al. CIRCULATION
- Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
- (2021) Jasper Tromp et al. EUROPEAN JOURNAL OF HEART FAILURE
- Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF
- (2020) Pooja Dewan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
- (2020) Matteo Serenelli et al. EUROPEAN HEART JOURNAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR‐Preserved Trial
- (2020) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
- (2020) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
- (2020) Piotr Ponikowski et al. LANCET
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus
- (2020) Chi Young Shim et al. CIRCULATION
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
- (2019) Scott D. Solomon et al. CIRCULATION
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
- (2018) Karen A. Hicks et al. CIRCULATION
- Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
- (2018) Lars H. Lund et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE
- (2016) Naoki Okumura et al. CIRCULATION
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
- (2015) Scott D. Solomon et al. EUROPEAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
- (2014) Jennifer K. Rogers et al. EUROPEAN JOURNAL OF HEART FAILURE
- Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT
- (2014) Hicham Skali et al. EUROPEAN JOURNAL OF HEART FAILURE
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
- (2008) Barry M. Massie et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started